DIECI, MARIA VITTORIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.082
EU - Europa 739
AS - Asia 502
SA - Sud America 8
OC - Oceania 2
AF - Africa 1
Totale 8.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.071
CN - Cina 396
IT - Italia 327
FI - Finlandia 128
SE - Svezia 112
GB - Regno Unito 71
IN - India 52
DE - Germania 50
HK - Hong Kong 27
IE - Irlanda 16
CA - Canada 11
VN - Vietnam 10
BR - Brasile 7
FR - Francia 7
BE - Belgio 6
PH - Filippine 6
UA - Ucraina 6
ES - Italia 4
NL - Olanda 4
JP - Giappone 3
AU - Australia 2
CH - Svizzera 2
IR - Iran 2
NP - Nepal 2
AL - Albania 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
KR - Corea 1
KZ - Kazakistan 1
MY - Malesia 1
OM - Oman 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
Totale 8.334
Salva come PNG Salva come JPEG
Città #
Fairfield 1.403
Woodbridge 728
Chandler 655
Ashburn 614
Houston 608
Seattle 478
Ann Arbor 463
Cambridge 461
Wilmington 427
Padova 154
San Diego 133
Medford 120
Princeton 120
Beijing 113
Des Moines 90
Helsinki 83
Roxbury 59
Nanjing 57
Boardman 40
Pune 35
London 30
Jinan 25
New York 24
Milan 23
Shenyang 22
Nanchang 18
Guangzhou 17
Dublin 16
Norwalk 14
Falls Church 13
Zhengzhou 12
Codogno 10
Dong Ket 10
Tianjin 10
Changsha 9
Hebei 9
Ningbo 9
Ogden 9
Chiswick 8
Hong Kong 8
Ottawa 8
Jiaxing 7
Rome 7
Selvazzano Dentro 7
Brussels 6
Hangzhou 6
Hefei 6
Redwood City 6
Washington 6
Florence 5
Haikou 5
Kharkiv 5
Kilburn 5
Lappeenranta 5
Columbus 4
Hounslow 4
Kunming 4
Los Angeles 4
New Bedfont 4
Paris 4
Rubano 4
Tappahannock 4
Todi 4
Vicenza 4
Bergamo 3
Bologna 3
Falkenstein 3
Hamburg 3
Taizhou 3
Venice 3
Acton 2
Ancona 2
Andrano 2
Ascoli Piceno 2
Avezzano 2
Baotou 2
Borås 2
Capo d'Orlando 2
Caserta 2
Chicago 2
Chioggia 2
Clermont-Ferrand 2
Council Bluffs 2
Fort Worth 2
Fuzhou 2
Lanzhou 2
Legnaro 2
Mabalacat 2
Monmouth Junction 2
Orange 2
Pasig 2
Perugia 2
Prescot 2
Rockville 2
Sale Marasino 2
San Giuliano Terme 2
Selargius 2
Sestu 2
Southwark 2
São Paulo 2
Totale 7.339
Salva come PNG Salva come JPEG
Nome #
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 178
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 171
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers 146
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 138
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 136
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 134
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 133
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 127
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 127
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 125
Immune characterization of breast cancer metastases: Prognostic implications 120
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 119
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 119
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 118
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 118
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 116
Escalation and de-escalation in HER2 positive early breast cancer 116
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 114
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 113
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 109
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 107
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 100
Olaparib for the treatment of breast cancer 100
Electrochemotherapy of superficial tumors – Current status:: Basic principles, operating procedures, shared indications, and emerging applications 100
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 99
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 97
Fat grafting for breast cancer patients: From basic science to clinical studies 95
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 91
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 91
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 90
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 90
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis 90
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 90
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 89
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 88
Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers 88
Quantification of residual risk of relapse in breast cancer patients optimally treated 87
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 87
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 87
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 85
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 84
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives 83
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer 83
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis 81
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. 81
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer 80
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents 79
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 78
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 75
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 75
Timing for starting second line therapy in recurrent ovarian cancer. 75
HER2-Positive Early Breast Cancer 74
PIK3CA: a Target or a Marker in Breast Cancers 73
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 71
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 70
Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. 69
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer 68
The Future of Chemotherapy in the Era of Personalized Medicine 66
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 66
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) 66
Landscape and evolution of therapeutic research for breast cancer patients 65
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy 65
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy 64
Whole exome sequencing of rare aggressive breast cancer histologies 62
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 61
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 61
GD2 expression in breast cancer 60
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 57
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 57
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer 54
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 54
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 54
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 54
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 54
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study [Ann Oncol, 25, (2015) 611-618] DOI: 10.1093/annonc/mdt556 53
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 53
Evolution of HER2-low expression from primary to recurrent breast cancer 53
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 52
Clinical development of mTOR inhibitors in breast cancer 51
186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial 50
Solitary biceps muscle metastasis from neuroendocrine breast tumor 50
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 46
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 46
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 45
Pregnancy after breast cancer in patients with germline BRCA mutations 44
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 44
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 42
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 42
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 41
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 40
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice 40
Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer 37
Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center 37
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 36
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 36
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 35
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 35
Olaparib for advanced breast cancer 33
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy 32
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 32
Totale 7.852
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.791
article - articoli 35.083
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 539
Totale 71.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019400 0 0 0 0 0 0 0 0 0 0 214 186
2019/20202.042 161 33 69 368 175 102 181 205 269 276 124 79
2020/20211.585 57 111 61 102 70 228 97 126 183 284 177 89
2021/20221.804 109 181 178 97 185 125 150 141 98 70 130 340
2022/20231.310 268 150 53 169 155 146 28 79 160 15 65 22
2023/2024689 79 96 97 62 60 112 69 40 25 49 0 0
Totale 8.610